Efficacy of secukinumab as first-line bDMARD versus standard of care in axial spondyloarthritis

Further Publications Rheumatology

Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head-to-head randomized phase IIIb study

Arthritis Rheumatol

Baraliakos X, Østergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, Navarro-Compán V, Hermann KGA, Kishimoto M, Lee EY, Gensler LS, Kiltz U, Eigenmann MF, Pertel P, Readie A, Richards HB, Porter B, Braun J

doi: 10.1002/art.42852

Further Publications Rheumatology

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study

Arthritis Rheumatol

Deodhar A, Supronik J, Kivitz A, Valenzuela G, Kapur K, Rohrer S, Dokoupilova E, Richards HB, Pavelka K

doi: 10.1002/art.42993

Further Publications Immunology

Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): An externally-controlled study

Clin Exp Immunol

Whalen J, Chandra A, Kracker S, Ehl S, Seidel MG, Gulas I, Dron L, Velummailum R, Nagamuthu C, Liu S, Tutein Nolthenius J, Maccari ME, European Society for Immunodeficiencies (ESID)-APDS Registry Working Party

doi: 10.1093/cei/uxae107

Further Publications Rheumatology

Sex-related differences in efficacy and safety outcomes in axial spondyloarthritis randomized clinical trials: A systematic literature review and meta-analysis

Arthritis Care Res (Hoboken)

Gao A, Pardo JP, Dang S, Gensler LS, Mease P, Eder L

doi: 10.1002/acr.25512

Further Publications Rheumatology

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology (Oxford)

Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Vaux T, Prajapati C, Manente M, Marten A, Gensler LS

doi: 10.1093/rheumatology/keaf009

Melanoma and Skin Cancer

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

J Clin Oncol

Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D

doi: 10.1200/JCO.24.01125

EULAR 2024

Juvenile Idiopathic Arthritis

Canakinumab is effective as a first-line steroid-free treatment for patients with systemic juvenile idiopathic arthritis

Further Publications Rheumatology

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Res Ther

Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Baraliakos X, Bu X, Lagunes-Galindo I, Song IH, Wung P, Kato K, Shmagel A

doi: 10.1186/s13075-024-03441-3

Further Publications Rheumatology

Low socioeconomic status and female sex are associated with worse functional status in axial spondyloarthritis

Arthritis Care Res (Hoboken)

Stovall R, Li J, Fitzpatrick J, Roberts E, Palmowski A, Anastasiou C, Izadi Z, Friedly J, Singh N, Gensler LS, Schmajuk G, Yazdany J

doi: 10.1002/acr.25436

Related content

Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head-to-head randomized phase IIIb study

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study

Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): An externally-controlled study

Sex-related differences in efficacy and safety outcomes in axial spondyloarthritis randomized clinical trials: A systematic literature review and meta-analysis

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Canakinumab is effective as a first-line steroid-free treatment for patients with systemic juvenile idiopathic arthritis

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Low socioeconomic status and female sex are associated with worse functional status in axial spondyloarthritis